Hutchmed (China) Limited (HCM) has released an update.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
HUTCHMED (China) Limited has commenced a Phase II/III clinical trial in China to assess a new treatment regimen for metastatic pancreatic ductal adenocarcinoma, combining their drug surufatinib with Hengrui Pharma’s camrelizumab and chemotherapy. The trial seeks to improve survival rates for a cancer with typically poor prognoses, as current treatments have shown limited efficacy. With this initiative, HUTCHMED aims to expand options for patients and potentially enhance their life expectancy.
For further insights into HCM stock, check out TipRanks’ Stock Analysis page.
